

Egypt Generic Drugs Market By Type (Small Molecule Generics v/s Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others), By Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House v/s Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) By Region, Competition, Forecast & Opportunities, 2028F

Market Report | 2023-08-01 | 77 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

Egypt Generic Drugs Market is expected to register a formidable growth during the forecast period on account of growing prevalence of chronic diseases. Chronic diseases, such as diabetes, hypertension, cardiovascular diseases, cancer, are among the most prevalent and can be debilitating, requiring lifelong treatment. According to International Diabetes Federation (IDF), estimated number of people in 1,000s between the age of 20-79 years in Egypt in 2021 were around 10,930.7. This number is set to increase to 19,975.3 by 2045. As the prevalence of chronic diseases continues to rise, so does the demand for affordable and effective medications, leading to an increased demand for generic drugs. Additionally, increasing geriatric population worldwide which is susceptible to various chronic diseases, injuries and falls is further expected to increase the demand for generic drugs. Additionally, growing geriatric population which is susceptible to various diseases is further expected to increase the demand for generic drugs, thereby driving the growth of Egypt generic drugs market. According to Central Agency for Public Mobilisation and Statistics (CAPMAS), Egypt's elderly population had reached 6.5 million, of which 3.5 million were males and 3 million females in 2019. The number has been significantly increasing since then, thereby driving the growth of Egypt generic drugs market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Benefits Associated with Generic Drugs

The low cost and easy availability are the major benefits which have significantly increased the demand for generic drugs over the last few years and will also support the growth of Egypt generic drugs market during the forecast period. The high cost of branded drugs is a significant factor driving the demand for generic drugs. Many people cannot afford the high prices of branded drugs, and generic drugs offer a more affordable alternative. Generic drugs are often priced at a fraction of the cost of branded drugs, making them accessible to a wider range of people. For example, according to FDA, on average, generic drugs cost 80-85% less than their branded counterparts. This cost saving can be significant, especially for people who require long-term medication or have chronic conditions that require multiple medications. This in turn is expected to support the growth of Egypt generic drugs market. Additionally, many generic drugs are available over-the-counter (OTC), meaning that they can be purchased without a prescription. This makes it easier for people to access medications they need without having to visit a doctor or obtain a prescription.

Supportive Government Policies & Initiatives

Government policies have played an important role in driving the growth of the generic drugs market in Egypt. The Egyptian government has implemented price regulations for both branded and generic drugs, which has helped to make medications more affordable for patients. This has increased demand for generic drugs, which are generally less expensive than their branded counterparts. Additionally, there is no competition issues associated with the generic entry of pharmaceuticals in Egypt. The registration of pharmaceutical products in Egypt includes a compulsory pricing phase, in which the Ministry of Health intervenes to determine the price of the product regardless of it being innovative. This compulsory pricing regime in turn helps in eliminating competition issues associated with the generic entry of pharmaceuticals. All these factors are expected to support the growth of Egypt generic drugs market in the coming years.

Furthermore, the government has implemented policies to promote local manufacturing of generic drugs, including tax incentives and support for research and development. This has helped to build a strong local industry, which has in turn contributed to the growth of the market. The government has implemented policies to increase access to healthcare for all citizens, including through the provision of free or subsidized healthcare services. This has increased demand for medications, including generic drugs, which are more affordable for patients. This in turn is expected to create lucrative opportunities for the growth of Egypt generic drugs market during the forecast period.

Improving Healthcare Infrastructure

As the healthcare infrastructure in Egypt expands, more people have access to healthcare services, including prescription medications. This has increased the demand for generic drugs, which are more affordable and accessible than branded drugs. The expansion of healthcare facilities in Egypt, including hospitals, clinics, and pharmacies, has created more opportunities for local manufacturers to distribute and sell generic drugs. This has contributed to the growth of the generic drugs market, as more patients have access to these medications. The growing healthcare infrastructure in Egypt has also led to improvements in logistics and distribution channels for medications, including generic drugs. This has made it easier for manufacturers to distribute their products across the country, increasing their reach and sales.

As the healthcare infrastructure in Egypt expands, there is a greater emphasis on preventive healthcare, including the use of medications to prevent and manage chronic diseases. This has increased the demand for generic drugs, which are commonly used to treat chronic conditions. The growing healthcare infrastructure in Egypt has also attracted investment in research and development of new generic drugs. This has led to the development of new and innovative medications that meet the needs of patients in the country. All these factors are expected to open new prospects for the growth of Egypt generic drugs market.

Market Segmentation

Egypt Generic Drugs market is segmented into type, application, drug delivery, form, source, distribution channel, region, and company. Based on type, Egypt Generic Drugs market is split into small molecule generics and biosimilars. Based on application, Egypt Generic Drugs market is categorized into cardiovascular diseases, diabetes, neurology, oncology, anti-inflammatory diseases, and others. In terms of drug delivery, Egypt Generic Drugs Market can be divided into oral, topical, parenteral, and others. By form, Egypt Generic Drugs Market can be fragmented into tablet, capsule, injection, and others. Based on source, Egypt Generic Drugs can be bifurcated into in-house and contract manufacturing organizations. By distribution channel, Egypt Generic Drugs Market can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Regionally, Egypt

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Generic Drugs market can be split into Cairo, Alexandria, Giza, Qalyubia, Port Said, Suez, and Rest of Egypt.

Market Players

Eva Pharma, Pharco Pharmaceuticals, Amoun Pharmaceutical Company S.A.E. ("Amoun"), Rameda Pharmaceutical Company, Delta Pharmaceutical Industries, Global Napi Pharmaceuticals (Global Pharmaceutical Group), Minapharm Pharmaceuticals Co., Adwia Pharmaceuticals Co., GlaxoSmithKline S.A.E, Sanofi Egypt, Hikma Pharmaceuticals Plc, Egyptian International Pharmaceutical Industries (EIPICO), Medical Union Pharmaceuticals, MDI Pharma, AstraZeneca Egypt, among others are some of the leading companies operating in the Egypt Generic Drugs Market.

Recent Developments

In June 2022, officials from India and Egypt met to discuss partnerships for pharmaceutical trade, regulatory cooperation, pharmaceutical education and research. India is focusing on Egypt as a gateway to North Africa for its pharmaceutical exports, and the African nation seeks to leverage Indian businesses to strengthen its active pharmaceutical ingredients market and domestic drugs production. However, there is a major challenge which needs to be addressed. India is not among the countries presently approved by Egyptian authorities for good manufacturing practices. Egypt is seeking to become the pharmaceutical hub supplying vaccines, drugs, medical devices for the domestic as well as across different African countries. With this meeting and further meeting sessions Egypt is looking forward to attracting Indian pharmaceutical companies to look at Egypt as a manufacturing base catering to the African and regional markets for medicines, serum and vaccines. This in turn will open new prospects for the growth of Egypt generic drugs market in the next few years.

In August 2022, Egyptian International Pharmaceutical Industries (EIPICO), the largest pharmaceutical company in Egypt by number of units, announced its plans of diversifying its production capacity by building the country's first biological & biosimilar production plant. With the set up of this manufacturing unit, EIPICO will become the first company in the Middle East and North Africa (MENA) region to produce biological products starting from the cell line to final dosage form.

Such developments are expected to support the growth of Egypt Generic Drugs Market in the next few years.

Report Scope:

In this report, Egypt Generic Drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

□□Egypt Generic Drugs Market, By Type:

- o□Small Molecule Generics

- o□Biosimilars

□□Egypt Generic Drugs Market, By Application:

- o□Cardiovascular Diseases

- o□Diabetes

- o□Neurology

- o□Oncology

- o□Anti-Inflammatory Diseases

- o□Others

□□Egypt Generic Drugs Market, By Drug Delivery:

- o□Oral

- o□Topical

- o□Parenteral

- o□Others

□□Egypt Generic Drugs Market, By Form:

- o□Tablet

- o□Capsule

- o□Injection

- o□Others

□□Egypt Generic Drugs Market, By Source:

- o□In-House

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Contract Manufacturing Organizations

- o Egypt Generic Drugs Market, By Distribution Channel:

- o Hospital Pharmacies

- o Retail Pharmacies

- o Online Pharmacies

- o Others

- o Egypt Generic Drugs Market, By Region:

- o Cairo

- o Alexandria

- o Giza

- o Qalyubia

- o Port Said

- o Suez

- o Rest of Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present Egypt Generic Drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- o Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validations

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Egypt Generic Drugs Market Outlook

4.1. Market Size & Forecast

4.1.1. By Value

4.2. Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.1.□By Type (Small Molecule Generics v/s Biosimilars)
- 4.2.2.□By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
- 4.2.3.□By Drug Delivery (Oral, Topical, Parenteral, Others)
- 4.2.4.□By Form (Tablet, Capsule, Injection, Others)
- 4.2.5.□By Source (In House v/s Contract Manufacturing Organizations)
- 4.2.6.□By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
- 4.2.7.□By Region
- 4.2.8.□By Company (2022)
- 4.3.□Market Map
- 4.3.1.□By Type
- 4.3.2.□By Application
- 4.3.3.□By Drug Delivery
- 4.3.4.□By Form
- 4.3.5.□By Source
- 4.3.6.□By Distribution Channel
- 4.3.7.□By Region
- 5.□Egypt Small Molecule Generic Drugs Market Outlook
- 5.1.□Market Size & Forecast
- 5.1.1.□By Value
- 5.2.□Market Share & Forecast
- 5.2.1.□By Application
- 5.2.2.□By Drug Delivery
- 5.2.3.□By Form
- 5.2.4.□By Source
- 5.2.5.□By Distribution Channel
- 6.□Egypt Biosimilar Generic Drugs Market Outlook
- 6.1.□Market Size & Forecast
- 6.1.1.□By Value
- 6.2.□Market Share & Forecast
- 6.2.1.□By Application
- 6.2.2.□By Drug Delivery
- 6.2.3.□By Form
- 6.2.4.□By Source
- 6.2.5.□By Distribution Channel
- 7.□Market Dynamics
- 7.1.□Drivers
- 7.2.□Challenges
- 8.□Market Trends & Developments
- 9.□Policy & Regulatory Landscape
- 10.□Egypt Generic Drugs Market: SWOT Analysis
- 11.□Porter's Five Forces Analysis
- 11.1.□Competition in the Industry
- 11.2.□Potential of New Entrants
- 11.3.□Power of Suppliers
- 11.4.□Power of Customers
- 11.5.□Threat of Substitute Products
- 12.□PESTLE Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13. □Egypt Economic Profile
- 14. □Competitive Landscape
 - 14.1. □Eva Pharma
 - 14.2. □Pharco Pharmaceuticals
 - 14.3. □Amoun Pharmaceutical Company S.A.E. ("Amoun")
 - 14.4. □Rameda Pharmaceutical Company
 - 14.5. □Delta Pharmaceutical Industries
 - 14.6. □Global Napi Pharmaceuticals (Global Pharmaceutical Group)
 - 14.7. □Minapharm Pharmaceuticals Co.
 - 14.8. □Adwia Pharmaceuticals Co.
 - 14.9. □GlaxoSmithKline S.A.E
 - 14.10. □Sanofi Egypt
 - 14.11. □Hikma Pharmaceuticals Plc
 - 14.12. □Egyptian International Pharmaceutical Industries (EIPICO)
 - 14.13. □Medical Union Pharmaceuticals
 - 14.14. □MDI Pharma
 - 14.15. □AstraZeneca Egypt
- 15. □Strategic Recommendations
- 16. About Us & Disclaimer

Egypt Generic Drugs Market By Type (Small Molecule Generics v/s Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others), By Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House v/s Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) By Region, Competition, Forecast & Opportunities, 2028F

Market Report | 2023-08-01 | 77 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-14"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com